Latest Breaking News On - St louis university school of medicine - Page 1 : comparemela.com

- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement in cognition over pre-treatment baseline now shown to be sustained over 18 months ABERDEEN, Scotland and SINGAPORE, Dec. 1, 2022 /PRNewswire/ TauRx Pharmaceuticals Ltd is a global leader in Tau-based research in Alzheimer's disease (AD), being the only company running late-stage clinical trials for a potential therapy designed to target the Tau pathology of Alzheimer's. Pathological aggregation of Tau correlates with clinical disease severity and brain atrophy. As a hallmark of the disease, it is recognised as a key target for disease modifying treatments. This approach by TauRx contrasts to many in t

United kingdomSan franciscoUnited statesGeorge grossbergSt louis university school of medicineUniversity of aberdeenTaurx pharmaceuticals ltdClinical trialsDirector divisionGeriatric psychiatry departmentBehavioural neuroscienceAu aggregation inhibitorS an oral drug witha strong safety profileAving no risk of amyloid related imaging abnormalities topline results for the phase 3 studyEre shared at the clinical trials in alzheimer 39s disease ctad conference on wednesday0th november 2022